CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2021 and Provides Business Update
CureVac N.V., a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), today announced financial results for the third quarter and first nine months of 2021 and provided a business update.